Biodexa Pharmaceuticals American Depositary Shs (BDRX) vs SciSparc (SPRC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Biodexa Pharmaceuticals American Depositary Shs is the larger company by market cap ($982,950 vs $481,603), about 2.0 times the size. On valuation, SciSparc trades at a lower trailing P/E (0.0x vs 0.0x for Biodexa Pharmaceuticals American Depositary Shs).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BDRX | SPRC |
|---|---|---|
| Share price | $1.88 | $0.1955 |
| Market cap | $982.95K | $481.60K |
| 1-day change | -3.85% | -34.83% |
| P/E ratio (TTM) | 0.00 | 0.00 |
| EPS (TTM) | $509.89 | $248.24 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $1.31M |
| Revenue growth (YoY) | — | -54.64% |
| Net income (latest FY) | — | $-6.28M |
| Gross margin | — | 38.74% |
| Operating margin | — | -560.18% |
| Net margin | — | -481.16% |
| 52-week high | $357.60 | $29.88 |
| 52-week low | $1.85 | $0.167 |
| Distance from 52-week high | -99.48% | -99.35% |
| Analyst consensus | none | — |
| Avg. price target upside | +375.20% | — |
| Average volume | 618.91K | 2.93M |
| Shares outstanding | 524.24K | 2.46M |
| Employees | 11 | 3 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Biodexa Pharmaceuticals American Depositary Shs is about 2.0 times larger than SciSparc by market value ($982.95K vs $481.60K).
- Biodexa Pharmaceuticals American Depositary Shs trades at a higher earnings multiple (0.0x vs 0.0x trailing P/E).
About Biodexa Pharmaceuticals American Depositary Shs
BDRX stock →Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan brain cancer. Its lead product candidate, Tolimidone, is a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes.
Health Care · Biotechnology: Pharmaceutical Preparations · 11 employees
About SciSparc
SPRC stock →SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution.
Health Care · Biotechnology: Pharmaceutical Preparations · 3 employees
BDRX vs SPRC FAQ
Which is bigger, Biodexa Pharmaceuticals American Depositary Shs or SciSparc?
Biodexa Pharmaceuticals American Depositary Shs (BDRX) is larger, with a market capitalization of $982.95K compared with $481.60K for SciSparc (SPRC).
Which has the lower P/E ratio, BDRX or SPRC?
SPRC has the lower trailing P/E at 0.0, versus 0.0 for BDRX. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Biodexa Pharmaceuticals American Depositary Shs and SciSparc in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.